BLOOD PRODUCT
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA) has issued a Special Notice regarding a sole-source procurement for blood products from Blood Centers of America, Inc. (BCA). This action is justified by a Justification for Other Than Full and Open Competition (J&A) for an urgent, one-time order to support contingency operations, with a required fulfillment date no later than June 16, 2026.
Purpose & Scope
This notice serves as a Justification for Other Than Full and Open Competition (J&A) for the urgent, sole-source acquisition of blood product units. The procurement is intended to meet immediate needs for contingency operations that cannot be fulfilled through full and open competition. Specific logistical and shelf-life factors necessitate this urgent order, requiring fulfillment by June 16, 2026. The requiring activity is the DHA Armed Services Blood Program Division (ASBPD).
Contract Details
- Type: Sole-Source Procurement under Simplified Acquisition Procedures (SAT)
- Contractor: Blood Centers of America, Inc.
- Period of Performance: Single purchase, with fulfillment required by June 16, 2026.
- Funding Type: Operations & Maintenance (O&M).
- Estimated Value: Not explicitly stated in the provided documents.
- Set-Aside: Sole Source (under SAT).
Justification for Sole Source
Market research indicates that while other major blood suppliers exist, an agreement between BCA and ABC limits the number of major civilian blood manufacturers. BCA is specifically noted as the only entity capable of producing 35-day shelf life LTOWB and 40-day liquid plasma, which are critical for certain requirements identified by the ASBPD. This unique capability, combined with the urgent nature of the requirement, justifies the sole-source award.
Submission & Evaluation
This document is a Justification for Other Than Full and Open Competition (J&A) and not a solicitation. Therefore, proposal submission and evaluation criteria are not applicable.
Agency & Contact
- Department: DEPT OF DEFENSE
- Sub-Tier: DEFENSE HEALTH AGENCY (DHA)
- Office: DEFENSE HEALTH AGENCY
- Contact: Nakaura C Yusuf (nakaura.yusuf.civ@health.mil, 703-681-5821)
- Place of Performance: VA, United States
Additional Notes
A formal Broad Agency Announcement (BAA) is anticipated but has not yet been awarded. The contracting activity is DHACA. This Special Notice was published on June 17, 2026.